Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04220827 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
A Phase 1 study of Clinical Stage IV Gastric Cancer AJCC v8 and Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT04220827 is a Phase 1 study of Clinical Stage IV Gastric Cancer AJCC v8 and Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants, below the 222-participant average among 17 other Clinical Stage IV Gastric Cancer AJCC v8 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04220827, a Phase 1 study of Clinical Stage IV Gastric Cancer AJCC v8 and Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions Studied
Interventions
- DRUG Paclitaxel
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04220827
The ClinicalTrials.gov registry entry for NCT04220827 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 17 other Clinical Stage IV Gastric Cancer AJCC v8 trials with a reported enrollment target (88% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Clinical Stage IV Gastric Cancer AJCC v8 appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel is the first listed.
NCT04220827 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04220827 about?
NCT04220827 is a clinical study titled "Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer". This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or b...
What is the current status of trial NCT04220827?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2019-12-06. Estimated completion is 2028-10-30.
What conditions does trial NCT04220827 study?
This clinical trial studies the following conditions: Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8.
What interventions are being tested in trial NCT04220827?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04220827?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04220827 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage IV Gastric Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
RECRUITING · Phase 1
-
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
RECRUITING · Phase 1
-
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
RECRUITING · Phase 1
-
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
ACTIVE NOT RECRUITING · Phase 1
-
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Clinical Stage IV Gastric Cancer AJCC v8
All registered trials for this condition
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.